The Wolf Administration is working to reduce over-prescribing of opioids through use of the the Prescription Drug Monitoring Program and prescribing guidelines.

This page describes information on the impacts of opioids on families and children.

View annual counts of Accidental or Undetermined overdose deaths for 2012 forward, including provisional estimates of annual counts of overdose deaths for recent years, as noted with an asterisk and the month the data was pulled.
NOTE: Finalized death records for overdose deaths are often delayed by 3-6 months. Counties labeled “no value” have data suppressed because the counts are between 1 and 9.

Overdose Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug-poisoning deaths are identified using underlying cause-of-death codes X40–X44, and Y10–Y14, and include the following:

- R99 when the Injury Description indicates an overdose death.

- X49 when literal COD is Mixed or Combined or Multiple Substance Toxicity, as these are likely drug overdoses

- X47 when substance indicated is difluoroethane, alone or in combination with other drugs

Source Pennsylvania Prescription Drug Monitoring Program*

* These data were supplied by the Bureau of Health Statistics and Registries, Harrisburg, Pennsylvania. The Bureau of Health Statistics and Registries specifically disclaims responsibility for any analyses, interpretations or conclusions.

- Estimates are broken down by type of drugs involved in the overdose

- Any Drug Overdose Death - all drug overdose deaths, regardless of type of drug involved, excluding alcohol only deaths

- Opioid Overdose Death - any overdose death involving opioids, prescription or illegal

View quarterly trends in overdose rates for Any Drug Overdoses, Any Opioid Overdoses and Heroin Overdoses at the state and county level.
Please see Overdose Data Technical Notes for additional details: : https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx

This page is part of the community impacts section and describes impacts on the economic cost of the opioid crisis by estimating lost wages.

View trends in overdose rates for Any Drug Overdoses, Any Opioid Overdoses and Heroin Overdoses at the state and county level.
Please see Overdose Data Technical Notes for additional details: http://www.health.pa.gov/Your-Department-of-Health/Offices%20and%20Bureaus/PaPrescriptionDrugMonitoringProgram/Documents/OverdoseDataTechnicalNotes.pdf

This dataset reports number of successful naloxone reversals by police officers, as self-reported by municipal police departments, Capitol Police, and Pennsylvania State police. The data is stratified by county and by year. Note that there is no legislation mandating that law enforcement report naloxone reversals to DDAP; these data represent voluntary self-reports from departments.
NA - Not applicable. No FIPS code or county code exist for Pennsylvania State Police and Capitol Police. Also, counties labelled “NA” do not have municipal police departments and are only covered by Pennsylvania State Police.

This dataset reports the name of the site, street address, city, county, zip code, telephone number, latitude, and longitude of Pennsylvania Single County Authorities (SCAs). SCAs receive state and federal dollars through contracts with the Department of Drug and Alcohol Programs (DDAP) to plan, coordinate, manage, and implement the delivery of drug and alcohol prevention, intervention, and treatment services at the local level.
The Pennsylvania Association of County Drug and Alcohol Administrators (PACDAA) is a professional association that represents the Single County Authorities (SCAs) across the commonwealth who receive state and federal dollars through contracts with the Department of Drug and Alcohol Programs (DDAP), to plan, coordinate, programmatically and fiscally manage and implement the delivery of drug and alcohol prevention, intervention, and treatment services at the local level.

SCAs also receive funding for treatment services from the PA Department of Human Services (DHS), Office of Mental Health and Substance Abuse Services (OMHSAS). These services funded by DHS are primarily targeted to individuals in non-hospital residential care who are eligible for Medical assistance, or to a continuum of treatment services for those individuals no longer eligible as a result of welfare reforms.​

This data set includes the estimated number of individuals in Pennsylvania with Drug Use Disorder, which is an approximation for Opioid Use Disorder prevalence. The estimates are developed by applying mortality weights derived from the CDC’s National Center for Health Statistics to statewide illicit drug use estimates from the National Survey on Drug Use and Health (NSDUH, sponsored by the Substance Abuse and Mental Health Services Administration).

View quarterly trends in opioid dispensation data for all Schedule II-V opioids.
Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx
More information from U.S. Department of Justice
https://www.deadiversion.usdoj.gov/schedules/
Schedule I Controlled Substances
Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.
Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4-methylenedioxymethamphetamine ("Ecstasy").
Schedule II/IIN Controlled Substances (2/2N)
Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence.
Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone.
Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®).
Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital.
Schedule III/IIIN Controlled Substances (3/3N)
Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®).
Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone.
Schedule IV Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances in Schedule III.
Examples of Schedule IV substances include: alprazolam (Xanax®), carisoprodol (Soma®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®).
Schedule V Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.
Examples of Schedule V substances include: cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, Phenergan with Codeine®), and ezogabine.